Skip to main content
CivicGate

HR 1143
Introduced Re-checks Congress.gov for new actions and updates the bill's status, and fills in any sponsors, committees, or related bills that are missing. It does not re-pull sponsors/cosponsors/committees/related — those rarely change — and it skips all work if nothing has changed upstream, so it's cheap to click.

Medicare IVIG Access Enhancement Act of 2025

To amend title XVIII of the Social Security Act to expand coverage of the in-home administration of intravenous immune globulin under the Medicare program.

Introduced Feb 7, 2025

Latest action (Feb 7, 2025) Referred to the Committee on Energy and Commerce, and in addition to the Committee on Ways and Means, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned.

Referred to
Ways and Means Committee Energy and Commerce Committee
Policy area
Health
Issues
Healthcare
Legislative subjects (5)
Drug therapyHealth care costs and insuranceHealth care coverage and accessMedicareNeurological disorders

Summary
  • Expands Medicare coverage of in-home intravenous immune globulin (IVIG) administration to include treatment of chronic inflammatory demyelinating polyneuropathy and multifocal motor neuropathy, effective January 1, 2027.
  • Maintains existing Medicare coverage of in-home IVIG for treatment of primary immune deficiency diseases.
  • Authorizes the Secretary of Health and Human Services to establish different payment rates for in-home IVIG administration based on the condition being treated.

AI-generated plain-language summary of the bill text — neutral, and may be imperfect. See the full text below for the exact wording.

Sponsor (1)
2 cosponsors

Money behind the sponsor

Top reported contributors to Adrian Smith’s campaign committee (2024 cycle) — who funds the bill’s sponsor, not a claim about this bill. Data from FEC.

  • SANDHILLS PUBLISHING $19,800
  • TREGO/DUGAN AVIATION OF GRAND ISLAND $6,600
  • HUB INTERNATIONAL $6,600
  • ALLEGIS $6,600
  • BAXTER AUTOMOTIVE GROUP $6,600

Organizations whose employees gave the most — itemized individual contributions grouped by the donor’s reported employer (FEC Schedule A). Full finance for Adrian Smith → · Outside spending →

Actions (2)
  1. Feb 7, 2025 Referred to the Committee on Energy and Commerce, and in addition to the Committee on Ways and Means, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned. · house
  2. Feb 7, 2025 Introduced in House

More bills on these subjects (8)

Other bills that carry the most legislative subjects in common with this one (topical discovery — distinct from the procedural related bills above).

  • HR 5304 — Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations Act, 2026 (shares 4 subjects)
  • HR 1 — An act to provide for reconciliation pursuant to title II of H. Con. Res. 14. (shares 4 subjects)
  • HR 6130 — ASAP Act (shares 3 subjects)
  • S 4189 — INSULIN Act of 2026 (shares 3 subjects)
  • HR 9393 — Lower Costs, More Transparency Act of 2026 (shares 3 subjects)
  • HR 9642 — Medicare Access to Rural Anesthesiology Act (shares 3 subjects)
  • HR 3108 — RPM Access Act (shares 3 subjects)
  • HR 3164 — Ensuring Community Access to Pharmacist Services Act (shares 3 subjects)

Similar bills (6)

Bills with similar text or summary — includes reintroductions across Congresses. Ranked by semantic similarity of the bill text (computed locally); a neutral discovery aid, not a claim the bills are duplicates.

  • HR 8528 — PI Post Acute Access Act · Introduced Apr 27, 2026 · Cong. 119 75%
  • HR 3007 — Medicare Protection Act of 2025 · Introduced Apr 24, 2025 · Cong. 119 69%
  • HR 3079 — Medicaid Empowerment Act of 2025 · Introduced Apr 29, 2025 · Cong. 119 68%
  • HR 1922 — Ensuring Access to Essential Drugs Act · Introduced Mar 6, 2025 · Cong. 119 68%
  • HJRES 58 — Providing for congressional disapproval under chapter 8 of title 5, United States Code, of the rule submitted by the Centers for Medicare & Medicaid Services relating to "Medicare Program; Calendar Year (CY) 2025 Home Health Prospective Payment System (HH PPS) Rate Update; HH Quality Reporting Program Requirements; HH Value-Based Purchasing Expanded Model Requirements; Home Intravenous Immune Globulin (IVIG) Items and Services Rate Update; and Other Medicare Policies". · Introduced Feb 12, 2025 · Cong. 119 67%
  • HR 2744 — Medicare Enrollment Protection Act of 2025 · Introduced Apr 8, 2025 · Cong. 119 67%

Text versions (1)
  • Introduced in House · Feb 7, 2025

Only one text version is on file, so there’s no earlier version to compare against yet.

Full text

IN THE HOUSE OF REPRESENTATIVES

February 7, 2025

Mr. Smith of Nebraska (for himself and Mr. Garamendi) introduced the following bill; which was referred to the Committee on Energy and Commerce, and in addition to the Committee on Ways and Means, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned

A BILL

To amend title XVIII of the Social Security Act to expand coverage of the in-home administration of intravenous immune globulin under the Medicare program.

Be it enacted by the Senate and House of Representatives of the United States of America in Congress assembled,

SECTION 1. SHORT TITLE.

This Act may be cited as the “Medicare IVIG Access Enhancement Act of 2025”.

SEC. 2. EXPANDING COVERAGE OF THE IN-HOME ADMINISTRATION OF INTRAVENOUS IMMUNE GLOBULIN UNDER THE MEDICARE PROGRAM.

(a) In General.—Section 1861 of the Social Security Act (42 U.S.C. 1395x) is amended—

(1) in subsection (s)(2)(Z), by inserting “(and, beginning January 1, 2027, for the treatment of chronic inflammatory demyelinating polyneuropathy and multifocal motor neuropathy)” after “primary immune deficiency diseases”; and

(2) in subsection (zz), by inserting “(or, beginning January 1, 2027, with diagnosed chronic inflammatory demyelinating polyneuropathy and multifocal motor neuropathy)” after “primary immune deficiency disease”.

(b) Authority for Variance in Payments.—Section 1842(o)(8) of the Social Security Act (42 U.S.C. 1395u(o)(8)) is amended by inserting “and may vary depending on whether such administration is related to treatment of a primary immune deficiency disease or the treatment of chronic inflammatory demyelinating polyneuropathy or multifocal motor neuropathy (as determined appropriate by the Secretary through notice and comment rulemaking)” after “of 2012”. <all>

Comments

Comments

Loading comments…